Salud financiera de hoja de balance de Taiwan Advance Bio-Pharmaceutical
Salud financiera controles de criterios 2/6
Taiwan Advance Bio-Pharmaceutical has a total shareholder equity of NT$228.8M and total debt of NT$279.1M, which brings its debt-to-equity ratio to 122%. Its total assets and total liabilities are NT$699.3M and NT$470.5M respectively. Taiwan Advance Bio-Pharmaceutical's EBIT is NT$30.2M making its interest coverage ratio 5. It has cash and short-term investments of NT$138.5M.
Información clave
122.0%
Ratio deuda-patrimonio
NT$279.08m
Deuda
| Ratio de cobertura de intereses | 5x |
| Efectivo | NT$138.51m |
| Patrimonio | NT$228.81m |
| Total pasivo | NT$470.50m |
| Activos totales | NT$699.32m |
Actualizaciones recientes sobre salud financiera
No hay actualizaciones
Análisis de la situación financiera
Pasivos a corto plazo: 4186's short term assets (NT$242.3M) do not cover its short term liabilities (NT$284.7M).
Pasivo a largo plazo: 4186's short term assets (NT$242.3M) exceed its long term liabilities (NT$185.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: 4186's net debt to equity ratio (61.4%) is considered high.
Reducción de la deuda: 4186's debt to equity ratio has increased from 85.2% to 122% over the past 5 years.
Cobertura de la deuda: 4186's debt is not well covered by operating cash flow (13.1%).
Cobertura de intereses: 4186's interest payments on its debt are well covered by EBIT (5x coverage).